Corpus overview


Overview

MeSH Disease

COVID-19 (191)

Fever (173)

Pneumonia (161)

Cough (64)

Dyspnea (57)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 201
    records per page




    Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety—Particularities in the Context of COVID-19 MESHD

    Authors: Ana Miruna Dragoi; Ioana Radulescu; Anca Lucia Pop; Bogdana Adriana Năsui; Valentin Varlas; Simona Trifu

    id:10.20944/preprints202009.0724.v2 Date: 2020-11-09 Source: Preprints.org

    Background: Clozapine (CLZ) use is precarious due to its neurological, cardiovascular, and hematological side effects; however, it is the gold standard in therapy-resistant schizophrenia MESHD schizophrenia HP (TRS) in adults TRANS and is underused. Objective: to examine the most recent CLZ data on (a) side effects concerning (b) recent pharmacological mechanisms, (c) therapy benefits, and (d) the particularities of the COVID-19 MESHD pandemic. Data sources: a search was performed in two databases (PubMed and Web of Science) using the specific keywords "clozapine" and " schizophrenia MESHD schizophrenia HP," "side effects," " agranulocytosis HP agranulocytosis MESHD," "TRS," or " bipolar affective disorder MESHD bipolar affective disorder HP ( BAF MESHD)" for the last ten years. Study eligibility criteria: clinical trials on adults TRANS with acute symptoms of schizophrenia HP schizophrenia MESHD or related disorders. Results: We selected 37 studies, randomized controlled trials (RCTs), and clinical case series (CCS), centered on six main topics in the search area: (a) CLZ in schizophrenia HP schizophrenia MESHD, (b) CLZ in bipolar disorder MESHD, (c) side effects during the clozapine therapy, (d) CLZ in pregnancy, (e) CLZ in early-onset schizophrenia HP schizophrenia MESHD, and (f) CLZ therapy and COVID-19 MESHD infection. Limitations: We considered RCTs and CCS from two databases, limited to the search topics. Conclusions and implications of key findings: (a) Clozapine doses should be personalized for each patient based on pharmacogenetics testing when available; the genetic vulnerability postulates predictors of adverse reactions' severity; patients with a lower genetic risk could have less frequent hematological monitoring; (b) CLZ-associated risk of pulmonary embolism HP pulmonary embolism MESHD imposes prophylactic measures for venous thromboembolism MESHD thromboembolism HP; (c) convulsive MESHD episodes are not an indication for stopping treatment; the plasma SERO concentration of clozapine is a better side effect predictor than the dosage; (d) COVID-19 MESHD infection may enhance clozapine toxicity MESHD, generating an increased risk of pneumonia HP pneumonia MESHD. Therapy must be continued with proper monitoring of the white blood SERO count, and the clozapine dose decreased by half until three days after the fever HP fever MESHD breaks; psychiatrists and healthcare providers must act together. Background: Clozapine (CLZ) use is precarious due to its neurological, cardiovascular, and hematological side effects; however, it is the gold standard in therapy-resistant schizophrenia HP schizophrenia MESHD (TRS) in adults TRANS and is underused. Objective: to examine the most recent CLZ data on (a) side effects concerning (b) recent pharmacological mechanisms, (c) therapy benefits, and (d) the particularities of the COVID-19 MESHD pandemic. Data sources: a search was performed in two databases (PubMed and Web of Science) using the specific keywords "clozapine" and " schizophrenia HP schizophrenia MESHD," "side effects," " agranulocytosis MESHD agranulocytosis HP," "TRS," or " bipolar affective disorder HP bipolar affective disorder MESHD ( BAF MESHD)" for the last ten years. Study eligibility criteria: clinical trials on adults TRANS with acute symptoms of schizophrenia HP schizophrenia MESHD or related disorders. Results: We selected 37 studies, randomized controlled trials (RCTs), and clinical case series (CCS), centered on six main topics in the search area: (a) CLZ in schizophrenia MESHD schizophrenia HP, (b) CLZ in bipolar disorder MESHD, (c) side effects during the clozapine therapy, (d) CLZ in pregnancy, (e) CLZ in early-onset schizophrenia MESHD schizophrenia HP, and (f) CLZ therapy and COVID-19 MESHD infection. Limitations: We considered RCTs and CCS from two databases, limited to the search topics. Conclusions and implications of key findings: (a) Clozapine doses should be personalized for each patient based on pharmacogenetics testing when available; the genetic vulnerability postulates predictors of adverse reactions' severity; patients with a lower genetic risk could have less frequent hematological monitoring; (b) CLZ-associated risk of pulmonary embolism HP pulmonary embolism MESHD imposes prophylactic measures for venous thromboembolism MESHD thromboembolism HP; (c) convulsive MESHD episodes are not an indication for stopping treatment; the plasma SERO concentration of clozapine is a better side effect predictor than the dosage; (d) COVID-19 MESHD infection may enhance clozapine toxicity MESHD, generating an increased risk of pneumonia HP pneumonia MESHD. Therapy must be continued with proper monitoring of the white blood SERO count, and the clozapine dose decreased by half until three days after the fever HP fever MESHD breaks; psychiatrists and healthcare providers must act together.

    Baseline characteristics, management, and outcomes of 55,270 children TRANS and adolescents diagnosed with COVID-19 MESHD and 1,952,693 with influenza in France, Germany, Spain, South Korea and the United States: an international network cohort study

    Authors: Talita Duarte-Salles; David Vizcaya; Andrea Pistillo; Paula Casajust; Anthony G. Sena; Lana Yin Hui Lai; Albert Prats-Uribe; Waheed-Ul-Rahman Ahmed; Thamir M Alshammari; Heba Alghoul; Osaid Alser; Edward Burn; Seng Chan You; Carlos Areia; Clair Blacketer; Scott DuVall; Thomas Falconer; Sergio Fernandez-Bertolin; Stephen Fortin; Asieh Golozar; Mengchun Gong; Eng Hooi Tan; Vojtech Huser; Pablo Iveli; Daniel R Morales; Fredrik Nyberg; Jose D. Posada; Martina Recalde; Elena Roel; Lisa M. Schilling; Nigam H. Shah; Karishma Shah; Marc A. Suchard; Lin Zhang; Andrew E. Williams; Christian G. Reich; Kristin Kostka; Daniel Prieto-Alhambra

    doi:10.1101/2020.10.29.20222083 Date: 2020-10-30 Source: medRxiv

    Objectives To characterize the demographics, comorbidities, symptoms, in-hospital treatments, and health outcomes among children TRANS/adolescents diagnosed or hospitalized with COVID-19 MESHD. Secondly, to describe health outcomes amongst children TRANS/adolescents diagnosed with previous seasonal influenza. Design International network cohort. Setting Real-world data from European primary care records (France/Germany/Spain), South Korean claims and US claims and hospital databases. Participants Diagnosed and/or hospitalized children TRANS/adolescents with COVID-19 MESHD at age TRANS <18 between January and June 2020; diagnosed with influenza in 2017-2018. Main outcome measures Baseline demographics and comorbidities, symptoms, 30-day in-hospital treatments and outcomes including hospitalization, pneumonia HP pneumonia MESHD, acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD), multi-system inflammatory syndrome MESHD (MIS-C), and death MESHD. Results A total of 55,270 children TRANS/adolescents diagnosed and 3,693 hospitalized with COVID-19 MESHD and 1,952,693 diagnosed with influenza were studied. Comorbidities including neurodevelopmental disorders MESHD, heart disease MESHD, and cancer MESHD were all more common among those hospitalized vs diagnosed with COVID-19 MESHD. The most common COVID-19 MESHD symptom was fever HP fever MESHD. Dyspnea HP Dyspnea MESHD, bronchiolitis MESHD bronchiolitis HP, anosmia and gastrointestinal symptoms MESHD anosmia and gastrointestinal symptoms HP were more common in COVID-19 MESHD than influenza. In-hospital treatments for COVID-19 MESHD included repurposed medications (<10%), and adjunctive therapies: systemic corticosteroids (6.8% to 37.6%), famotidine (9.0% to 28.1%), and antithrombotics such as aspirin (2.0% to 21.4%), heparin (2.2% to 18.1%), and enoxaparin (2.8% to 14.8%). Hospitalization was observed in 0.3% to 1.3% of the COVID-19 MESHD diagnosed cohort, with undetectable (N<5 per database) 30-day fatality. Thirty-day outcomes including pneumonia MESHD pneumonia HP, ARDS MESHD, and MIS-C were more frequent in COVID-19 MESHD than influenza. Conclusions Despite negligible fatality, complications including pneumonia HP pneumonia MESHD, ARDS MESHD and MIS-C were more frequent in children TRANS/adolescents with COVID-19 MESHD than with influenza. Dyspnea HP Dyspnea MESHD, anosmia and gastrointestinal symptoms MESHD anosmia and gastrointestinal symptoms HP could help differential diagnosis. A wide range of medications were used for the inpatient management of pediatric COVID-19 MESHD.

    Tocilizumab is associated with reduction in inflammation MESHD and improvement in P/F ratio in critically sick COVID19 MESHD patients

    Authors: Muhammad Asim Rana; Mubashar Sultan Hashmi; Muhammad Muneeb Ullah Saif; Muhammad Faisal Munir; Ahad Qayyum; Rizwan Pervaiz; Muhammad Mansoor Hafeez; Graham Cooke; Timothy B Hallett; Katharina D Hauck; Peter J White; Mark R Thursz; Shevanthi Nayagam; Brendan Flannery; Ricardo Gilead Baibich; Iris Bigler; Matan Malul; Rotem Rishti; Asher Brenner; Yair E. Lewis; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.20.20210195 Date: 2020-10-21 Source: medRxiv

    Introduction: Coronavirus disease 2019 MESHD was initially detected in China and has been declared a global pandemic by World Health Organization on March 11, 2020. In the majority of patients, SARS-CoV-2 causes a mild to moderate illness characterized by fever MESHD fever HP and respiratory symptoms MESHD, with or without evidence of pneumonia HP pneumonia MESHD. The recent studies suggest that anti-cytokine targeted therapies might be associated with benefit for patients with severe COVID-19 MESHD especially in improving respiratory failure HP respiratory failure MESHD. Tocilizumab, a monoclonal antibody SERO against interleukin 6 (IL6) receptor, is associated with clinical benefit for COVID-19 MESHD patients as it inhibits IL6 and decreases inflammation MESHD. Methods: As Tocilizumab has been an important part of our treatment and a strict criterion was followed to administer Tocilizumab, a retrospective study design used to assess the beneficial effects of Tocilizumab in improvement of ratio partial pressure of arterial Oxygen and fraction of inspired Oxygen (PaO2/FiO2 or P/F ratio) and C- reactive protein (CRP) in COVID19 MESHD patients has been done. 60 patients were taken for this study by using convenient sampling technique the data of demographics, laboratory results, and clinical outcomes i.e. improvement of respiratory failure MESHD respiratory failure HP depicted in the form of PF Ratio were obtained from the medical records, Statistical analysis was done with SPSS, version 21.0. Results: Sixty patients (47 males TRANS and 13 females TRANS) with COVID-19 MESHD were included in this study, the mean age TRANS of patients was 53.83 (14-81) years. After administration of Tocilizumab the lab parameters were changed as CRP decreased down to .40 (9.6-73) mg/L but other parameters were not affected. The PF ratio improved in COVID-19 MESHD patients after administration of Tocilizumab the median of PF Ratio before treatment was 108 (52-362) and improved up to 128 (37-406) after Tocilizumab therapy. Conclusion: In summary, Tocilizumab appears to be associated with improvement in P/F Ratio and CRP in COVID19 MESHD patients but other markers did not improve in response to Tocilizumab therapy in severely ill COVID-19 MESHD patients.

    A case report of greater saphenous vein thrombosis MESHD in a patient with coronavirus ( COVID-19 MESHD) infection

    Authors: Negin Hesam-Shariati; Poya Fatehi; Fardin Fathi; Morteza Abouzaripour; Mohamad Bakhtiar Hesam Shariati

    doi:10.21203/rs.3.rs-86688/v1 Date: 2020-10-01 Source: ResearchSquare

    In December 2019, the World Health Organization (WHO) announced a series of pneumonia MESHD pneumonia HP cases caused by an unknown origin, discovered in Wuhan, China. A dangerous virus called SARS-Cov-2 (severe acute respiratory syndrome coronavirus 2) caused a disease named acute respiratory syndrome MESHD, which was later popularly called coronavirus infection MESHD ( COVID-19 MESHD). Patients with acute COVID-19 MESHD are at high risk for thrombosis MESHD in various blood SERO vessels due to over-coagulation, blood SERO stasis, and endothelial damage. To date, very little research has been done on the number and side effects of thromboembolic disorders MESHD in patients with COVID-19 MESHD. In this study, we report a case with COVID-19 MESHD, who was hospitalized in one of the hospitals in Sanandaj, Iran. There were symptoms of fever HP fever MESHD, chills HP, muscle aches MESHD, cough HP, and tachycardia HP tachycardia MESHD. Laboratory tests such as CRP, ESR, Ferritin CLIA, LDH and D-Dimer were observed in this patient at a high level. Doppler ultrasound of this patient revealed an abnormal finding, thrombosis MESHD in the right greater saphenous vein. This suggests that COVID-19 MESHD may lead to other side effects through damage to blood SERO vessels.

    Clozapine. Pharmacodynamic Mechanisms, Potential Pharmacogenetic Biomarkers, and Risks in Schizophrenia MESHD Schizophrenia HP. Particularities in the Context of Covid-19 MESHD. An Updated Overview

    Authors: Ana Miruna Dragoi; Ioana Radulescu; Anca Lucia Pop; Bogdana Adriana Năsui; Valentin Varlas; Simona Trifu

    id:202009.0724/v1 Date: 2020-09-30 Source: Preprints.org

    Background: Clozapine use is precarious due to its side effects - neurological, cardiovascular, and hematological; however, it is the gold standard in the therapy of resistant schizophrenia HP schizophrenia MESHD (TRS) in adults TRANS and harshly underused. Objective: Our purpose is to systematically examine the most recent data regarding clozapine in order to update the knowledge in pharmacological mechanisms, therapy benefits versus side effects to optimize its use in the context of a narrow and scarce of resources pathology, with particularities in the COVID-19 MESHD pandemic. (2) Data sources: We performed an accurate search in the primary sources of Databases (PubMed, BMC Public Health, Global Health, Cross Ref, Scopus, Web of Science, and Google Scholar) with specific keywords: “clozapine” and “ schizophrenia MESHD,” “risks” agranulocytosis MESHD” “TRS” “ bipolar affective disorder MESHD” “pregnancy” “early-onset schizophrenia MESHD” “resistance”. Study eligibility criteria: we extracted information regarding drug treatment, side effects profile, and efficacy for each trial; (3) Results: Of all the searched data we selected RCT’s, C.T.’s, reviews, systematic reviews, and meta-analyses; Data were converted and analyzed in a random-effects model. We included 45 studies, centered on six main topics in the search area: (a) treatment-resistant schizophrenia MESHD schizophrenia HP, (b) use in bipolar disorder MESHD, (c) side effects during the clozapine therapy - agranulocytosis MESHD agranulocytosis HP, metabolic side effects, pharmacogenetic severity markers, dysmetabolic MESHD side effects, pulmonary embolism HP pulmonary embolism MESHD, seizure HP seizure MESHD risk – (d) safety of clozapine in pregnancy, (e) clozapine resistance and ECT augmentation, (f) clozapine therapy and COVID-19 MESHD infection. Limitations: _______(4) Conclusions and implications of key findings: (a) The genetic vulnerability postulates predictors of severity so clozapine doses should be personalises for each patient based on pharmacogenetic testing; patients with a lower genetic risk may benefit from a more relaxed hematological monitoring schedule; (b) Pulmonary embolism MESHD Pulmonary embolism HP associated with clozapine has a mortality rate of 36.36%, prophylactic measures for venous thromboembolism MESHD thromboembolism HP for six months after initiating therapy is mandatory; (c) Convulsive MESHD episodes are not an indication for stopping the treatment, side effect (s.e.) incidence increases with the dose, the plasma SERO concentration of clozapine (1300 ng/ml) it is a better s. e. predictor than the dosage; (d) clozapine refractory improves up to 69% early-onset schizophrenia MESHD schizophrenia HP, assesed by the Brief Psychiatric Rating Scale (BPRS) (e) more pharmacogenetic studies of the Romanian schizophrenic MESHD patients are needed in relation with the clozapine therapy in order to define more precise safety margins; (f) COVID-19 MESHD infection may enhance clozapine toxicity MESHD generating an increased risk of pneumonia HP pneumonia MESHD therapy must be continued with proper monitoring of the white blood SERO count and with the decrease of the clozapine dose by half until three days after the subside of the fever MESHD fever HP; psychiatrists and healthcare providers must act togheder. As in the past four decades, research has failed to generate effective novel psycho-pharmaceuticals, there is an urgent need to enhance the access to clozapine for people with TRS at the worldwide level. The progress of pharmacogenetic researches, endocrinology, genetic testing - offer the psychiatrists nowadays the chance to use this drug at its highest potential in a personalized manner for every patient - minimizing the adverse side-effects.

    Clozapine. Pharmacodynamic Mechanisms, Potential Pharmacogenetic Biomarkers, and Risks in Schizophrenia MESHD Schizophrenia HP. Particularities in the Context of Covid-19 MESHD. An Updated Overview

    Authors: Ana Miruna Dragoi; Ioana Radulescu; Anca Lucia Pop; Bogdana Adriana Năsui; Valentin Varlas; Simona Trifu

    id:10.20944/preprints202009.0724.v1 Date: 2020-09-30 Source: Preprints.org

    Background: Clozapine use is precarious due to its side effects - neurological, cardiovascular, and hematological; however, it is the gold standard in the therapy of resistant schizophrenia HP schizophrenia MESHD (TRS) in adults TRANS and harshly underused. Objective: Our purpose is to systematically examine the most recent data regarding clozapine in order to update the knowledge in pharmacological mechanisms, therapy benefits versus side effects to optimize its use in the context of a narrow and scarce of resources pathology, with particularities in the COVID-19 MESHD pandemic. (2) Data sources: We performed an accurate search in the primary sources of Databases (PubMed, BMC Public Health, Global Health, Cross Ref, Scopus, Web of Science, and Google Scholar) with specific keywords: “clozapine” and “ schizophrenia MESHD,” “risks” agranulocytosis MESHD” “TRS” “ bipolar affective disorder MESHD” “pregnancy” “early-onset schizophrenia MESHD” “resistance”. Study eligibility criteria: we extracted information regarding drug treatment, side effects profile, and efficacy for each trial; (3) Results: Of all the searched data we selected RCT’s, C.T.’s, reviews, systematic reviews, and meta-analyses; Data were converted and analyzed in a random-effects model. We included 45 studies, centered on six main topics in the search area: (a) treatment-resistant schizophrenia MESHD schizophrenia HP, (b) use in bipolar disorder MESHD, (c) side effects during the clozapine therapy - agranulocytosis MESHD agranulocytosis HP, metabolic side effects, pharmacogenetic severity markers, dysmetabolic MESHD side effects, pulmonary embolism HP pulmonary embolism MESHD, seizure HP seizure MESHD risk – (d) safety of clozapine in pregnancy, (e) clozapine resistance and ECT augmentation, (f) clozapine therapy and COVID-19 MESHD infection. Limitations: _______(4) Conclusions and implications of key findings: (a) The genetic vulnerability postulates predictors of severity so clozapine doses should be personalises for each patient based on pharmacogenetic testing; patients with a lower genetic risk may benefit from a more relaxed hematological monitoring schedule; (b) Pulmonary embolism MESHD Pulmonary embolism HP associated with clozapine has a mortality rate of 36.36%, prophylactic measures for venous thromboembolism MESHD thromboembolism HP for six months after initiating therapy is mandatory; (c) Convulsive MESHD episodes are not an indication for stopping the treatment, side effect (s.e.) incidence increases with the dose, the plasma SERO concentration of clozapine (1300 ng/ml) it is a better s. e. predictor than the dosage; (d) clozapine refractory improves up to 69% early-onset schizophrenia MESHD schizophrenia HP, assesed by the Brief Psychiatric Rating Scale (BPRS) (e) more pharmacogenetic studies of the Romanian schizophrenic MESHD patients are needed in relation with the clozapine therapy in order to define more precise safety margins; (f) COVID-19 MESHD infection may enhance clozapine toxicity MESHD generating an increased risk of pneumonia HP pneumonia MESHD therapy must be continued with proper monitoring of the white blood SERO count and with the decrease of the clozapine dose by half until three days after the subside of the fever MESHD fever HP; psychiatrists and healthcare providers must act togheder. As in the past four decades, research has failed to generate effective novel psycho-pharmaceuticals, there is an urgent need to enhance the access to clozapine for people with TRS at the worldwide level. The progress of pharmacogenetic researches, endocrinology, genetic testing - offer the psychiatrists nowadays the chance to use this drug at its highest potential in a personalized manner for every patient - minimizing the adverse side-effects.

    Epidemiological and Clinical Characteristics and Risk Factors for Mortality of Inpatients with COVID-19 MESHD in Golestan Province, Iran: A Retrospective Cohort Study

    Authors: Mohammad Reza Honarvar; Gholamreza Roshandel; Hesamaddin Shirzad-Aski; Alijan Tabarraei; Alireza Tahamtan; Mousa Ghelichi-Ghojogh; Abdolreza Fazel; Serajeddin Arefnia; Nahid Jafari; Mohsen Mansoury; Abdolhalim Rajabi

    doi:10.21203/rs.3.rs-80960/v1 Date: 2020-09-20 Source: ResearchSquare

    Background: Coronavirus disease 2019 MESHD ( COVID-19 MESHD) is an emerging infectious disease MESHD that was first reported in Wuhan, China, and has subsequently spread worldwide. We aimed to further clarify the epidemiological and clinical characteristics of 2019-nCoV pneumonia MESHD pneumonia HP and risk factors associated for mortality. Methods: In this retrospective cohort study, we included inpatient with acute respiratory distress syndrome MESHD respiratory distress HP syndrome at Golestan University of Medical Sciences Hospitals (Golestan province, Iran) who had been discharged or had died in 2020. Epidemiological, clinical, and laboratory data, including samples for viral RNA detection, were extracted from electronic medical records and compared between recovered and died cases. We used multiple logistic regression methods to explore the risk factors associated with in-hospital death MESHD.Results: In overall 2,835 acute respiratory distress syndrome MESHD respiratory distress syndrome HP patients were included in this study, of these patients, 874 (30.83.9%) were positive for 2019­nCoV, and 1,046 (36.90%) were negative and 915 (32.28%) were not available for PCR result. Five hundred and sixty-three patients (19.86%) died, 1,687 patients (59.51%) were recovered, and 585 (20.63%) under treatment. Of the total deaths, only 288 (10.15%) were attributed to COVID-19 MESHD. The most common symptoms at onset TRANS of illness were respiratory distress HP (1,795 [63.32%]), fever MESHD fever HP (1,601 [56.47%]), dry cough MESHD cough HP (1,595 [56.26%]), Sore throat (445 [15.70%]), and myalgia MESHD myalgia HP (342 [12.06%]).One thousand and twelve (35.7%) had 1 or more coexisting medical conditions. In multiple logistic regression analysis, risk factors associated with the death included older age TRANS (OR (Odds Ratio), 1.03; 95% CI; 1.02-1.04), blood SERO oxygen level (SpO2<93%) (OR, 2.44; 95% CI; 1.79-3.31), comorbidities (OR, 2.15; 95% CI; 1.62-2.84), respiratory distress HP (OR, 1.74; 95% CI; 1.28-2.37), and headache HP headache MESHD (OR, 0.44 95% CI; 0.21-0.92). Conclusions: The 2019-nCoV infection MESHD caused collections of severe respiratory illness MESHD and was associated high ratio of hospitalization in ICU and high mortality. Older age TRANS and comorbidities were associated with more risk of death MESHD among patients with 2019­nCoV. 

    Pulmonary fibrosis HP Pulmonary fibrosis MESHD and its related factors in discharged patients with new coronavirus pneumonia MESHD pneumonia HP: A cohort study of 90-150 days follow-up after onset

    Authors: Xiaohe Li; Chenguang Shen; Lifei Wang; Sumit Majumder; Die Zhang; M. Jamal Deen; Yanjie Li; Ling Qing; Ying Zhang; Chuming Chen; Rongrong Zou; Jianfeng Lan; Ling Huang; Cheng Peng; Lijiao Zeng; Yanhua Liang; Mengli Cao; Yang Yang; Minghui Yang; Guoyu Tan; Shenghong Tang; Lei Liu; Jing Yuan; Yingxia Liu

    doi:10.21203/rs.3.rs-79977/v1 Date: 2020-09-18 Source: ResearchSquare

    Background: Thousands of the Coronavirus Disease 2019 MESHD ( COVID-19 MESHD) patients have been discharged from hospitals, long-term follow-up studies are required to evaluate the prevalence SERO of post- COVID-19 MESHD fibrosis MESHD.Methods: This study involves 462 laboratory confirmed patients with COVID-19 MESHD who were admitted to Shenzhen Third People’s Hospital from January 11, 2020 to April 26, 2020. A total of 457 patients underwent thin-section chest CT scans during the hospitalization or after discharge to identify the pulmonary lesion MESHD. A total of 289 patients were followed up from 90 days to 150 days after the onset of the disease.Results:  Parenchymal bands, irregular interfaces, meshwork and traction bronchiectasis HP were the most common CT features in all COVID-19 MESHD patients. 86.87%, 74.40%, 79.56%, 68.12% and 62.03% patients developed with pulmonary fibrosis MESHD pulmonary fibrosis HP and 4.53%, 19.61%, 18.02%, 38.30% and 48.98% patients reversed pulmonary fibrosis MESHD pulmonary fibrosis HP during the 0-30, 31-60, 61-90, 91-120 and >120 days after onset, respectively. It was observed that Age TRANS, BMI, Fever HP Fever MESHD, and Highest PCT were predictive factors for sustaining fibrosis MESHD even after 90 days from onset. A predictive model of the persistence with pulmonary fibrosis MESHD pulmonary fibrosis HP was developed based-on the Logistic Regression method with an accuracy, PPV, NPV, Sensitivity SERO and Specificity of the model of 76%, 71%, 79%, 67%, and 82%, respectively. Only a fraction of COVID-19 MESHD patients suffered with abnormal lung function MESHD after 90 days from onset, and the ratio of abnormal lung function did not differ on a statistically significant level between the fibrotic and non-fibrotic groups.Conclusions: Long-term pulmonary fibrosis MESHD pulmonary fibrosis HP was more likely to develop in patients with older age TRANS, high BMI, severe/critical condition, fever HP fever MESHD, long time to turn the viral RNA negative, pre-existing disease and delay to admission. Fibrosis MESHD developed in COVID-19 MESHD patients could be reversed in about a half of the patients after 120 days from onset. The pulmonary function of most of COVID-19 MESHD patients with pulmonary fibrosis HP pulmonary fibrosis MESHD could turn to normal condition after three months from onset. An effective prediction model with an average Area Under the Curve (AUC) of 0.84 was established to predict the persistence of pulmonary fibrosis HP pulmonary fibrosis MESHD in COVID-19 MESHD patients for early diagnosis.

    Predicting clinical outcome with phenotypic clusters in COVID-19 MESHD pneumonia HP pneumonia MESHD: 2 an analysis of 12,066 hospitalized patients from the Spanish registry SEMI-3 COVID-19 MESHD.

    Authors: Manuel Rubio-Rivas; Xavier Corbella; Jose Maria Mora-Lujan; Jose Loureiro Amigo; Almudena Lopez Sampalo; Carmen Yera Bergua; Pedro Jesus Esteve Atienzar; Luis Felipe Diez Garcia; Ruth Gonzalez Ferrer; Susana Plaza Canteli; Antia Perez Pineiro; Begona Cortes Rodriguez; Leyre Jorquer Vidal; Ignacio Perez Catalan; Marta Leon Tellez; Jose Angel Martin Oterino; Maria Candelaria Martin Gonzalez; Jose Luis Serrano Carrillo de Albornoz; Eva Garcia Sardon; Jose Nicolas Alcala Pedrajas; Anabel Martin Urda Diez Canseco; Maria Jose Esteban Giner; Pablo Telleria Gomez; Ricardo Gomez Huelgas; Jose Manuel Ramos Rincon; Nina la Cour Freiesleben; Henriette Svarre Nielsen

    doi:10.1101/2020.09.14.20193995 Date: 2020-09-15 Source: medRxiv

    (1) Background: This study aims to identify different clinical phenotypes in COVID-19 MESHD 88 pneumonia HP pneumonia MESHD using cluster analysis and to assess the prognostic impact among identified clusters in 89 such patients. (2) Methods: Cluster analysis including 11 phenotypic variables was performed in a 90 large cohort of 12,066 COVID-19 MESHD patients, collected and followed-up from March 1, to July 31, 2020, 91 from the nationwide Spanish SEMI- COVID-19 MESHD Registry. (3) Results: Of the total of 12,066 patients 92 included in the study, most were males TRANS (7,052, 58.5%) and Caucasian (10,635, 89.5%), with a mean 93 age TRANS at diagnosis of 67 years (SD 16). The main pre-admission comorbidities were arterial 94 hypertension HP hypertension MESHD (6,030, 50%), hyperlipidemia MESHD hyperlipidemia HP (4,741, 39.4%) and diabetes mellitus HP diabetes mellitus MESHD (2,309, 19.2%). The 95 average number of days from COVID-19 MESHD symptom onset TRANS to hospital admission was 6.7 days (SD 7). 96 The triad of fever MESHD fever HP, cough MESHD cough HP, and dyspnea HP dyspnea MESHD was present almost uniformly in all 4 clinical phenotypes 97 identified by clustering. Cluster C1 (8,737 patients, 72.4%) was the largest, and comprised patients 98 with the triad alone. Cluster C2 (1,196 patients, 9.9%) also presented with ageusia and anosmia MESHD anosmia HP; 99 cluster C3 (880 patients, 7.3%) also had arthromyalgia, headache MESHD headache HP, and sore throat; and cluster C4 100 (1,253 patients, 10.4%) also manifested with diarrhea MESHD diarrhea HP, vomiting HP vomiting MESHD, and abdominal pain HP abdominal pain MESHD. Compared to 101 each other, cluster C1 presented the highest in-hospital mortality (24.1% vs. 4.3% vs. 14.7% vs. 102 18.6%; p<0.001). The multivariate study identified phenotypic clusters as an independent factor for 103 in-hospital death. (4) Conclusion: The present study identified 4 phenotypic clusters in patients with 104 COVID-19 MESHD pneumonia HP pneumonia MESHD, which predicted the in-hospital prognosis of clinical outcomes.

    Respiratory Rehabilitation After Blood SERO Transfusion in a COVID-19 MESHD Patient: A Case Report

    Authors: Mohammad Javad Mousavi; Narges Obeidi; Saeed keshmiri; Farzan Azodi; Jamile Kiyani; Farhad Abbasi

    doi:10.21203/rs.3.rs-78131/v1 Date: 2020-09-15 Source: ResearchSquare

    Background: The coronavirus disease 2019 MESHD ( COVID-19 MESHD), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been identified as the most crucial threat of the century. Due to severe pneumonia MESHD pneumonia HP and acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD), the SARS-CoV-2 can cause shortness of breath MESHD, hypoxemia MESHD hypoxemia HP, and the need to mechanical ventilation, intensive care unit (ICU) management, and eventual death MESHD. We have tried to use a non-invasive approach to prevent patient from needing respiratory support with invasive ventilation (IV). Here, for the first time, improvement of oxygen delivery and oxygen saturation levels were observed in a COVID-19 MESHD patient using packed red blood SERO cells (PRBCs) transfusion.Case presentation: A 63-year-old man with a history of smoking and addiction who came to our hospital facility with fever HP fever MESHD, shortness of breath MESHD and decreased blood SERO oxygen saturation. High-resolution chest CT revealed bilateral and multifocal ground-glass opacities consistent with COVID-19 MESHD. Subsequently, the COVID-19 MESHD infection was confirmed TRANS by real-time polymerase chain reaction (qRT-PCR) assay of the upper respiratory tract. Conclusions: Oxygen delivery and oxygen saturation improvement were observed in the COVID-19 MESHD patient, after PRBCs transfusions.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.